We illuminated that β-elemene acted as an anticancer agent in lung cancer via the regulation of METTL3-mediated PTEN pathway in a m6A manner, which disclosed a novel mechanism of β-elemene suppressing lung cancer development and provided convincing evidence supporting β-elemene as a potent for the administration of lung cancer. The gene discussed is METTL3; the disease is lung carcinoma.